Loxo Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Loxo Oncology, Inc.
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
The collaboration between the Swiss major and Blueprint Medicines, which could be worth up to $1.7bn, should help pralsetinib provide stiff competition to Eli Lilly's RET mutation drug Retevmo.
The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.
The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch.